• Genexine’s Nov. 2, 2026, correction removed data center businesses from proposed additions to its corporate business purposes.
• Proposed additions retain information and communications services, manufacturing and services related to AI medical robotics and mobility.
• The revised proposal focuses on medical AI expansion; shareholders will vote on the articles amendment Nov. 20, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genexine Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261102900843), on November 02, 2026, and is solely responsible for the information contained therein.